Project Grant HT94252510768
Award Date
8/1/25
Completion Date
7/31/26
Dollars Obligated
$654K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
The Defense Health Agency awarded Brigham & Women's Hospital Inc. a $253,636 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2025 to investigate the role of the secreted factor CTHRC1 in the pathogenesis of tuberous sclerosis complex. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care...
The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
This $1,016,449.00 Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports single-cell studies of immune-mediated injury and immunoregulation in human vascular composite allograft (VCA) rejection, with a performance period from August 1, 2024 to July 31, 2027. The award was granted to Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in...
This Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) in the amount of $793,572.00 is effective August 15, 2024 and runs through August 14, 2027. The award has been transferred from the General Hospital Corporation to Brigham and Women's Hospital Inc. in Boston, MA. The grant will fund a research project titled "A NOVEL TRANSLATIONAL MECHANISM UNDERLYING TSC PATHOPHYSIOLOGY". Brigham and Women's Hospital, a prominent...
Brigham & Women's Hospital Inc. was awarded a $596,016 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2027 to investigate environmental and gut-brain axis determinants of cognitive outcomes in Parkinson's disease. As the primary awardee, Brigham & Women's Hospital will leverage its expertise in biomedical research and healthcare services...
This $483,548.00 Project Grant was awarded on August 1, 2024 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports "SINGLE-CELL STUDIES OF IMMUNE-MEDIATED INJURY AND IMMUNOREGULATION IN HUMAN VCA REJECTION" at Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston, Massachusetts. The research funded by this grant aims to advance the understanding of...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
This $178,999 federal Project Grant, awarded on May 15, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Brigham & Women's Hospital Inc. to target TFE3 fusion proteins using PROTAC (Proteolysis Targeting Chimera) in translocation renal cell carcinoma (TRCC). The research aims to transform healthcare for military service members, veterans, and the broader public by developing innovative medical solutions. Brigham...